First meetings between CADAP and the authorities of Kyrgyzstan and Kazakhstan to identify the main objectives for action on drugs in Central Asia
The Central Asia Action Program on Drugs (CADAP) has begun the process of consultations with the authorities of Kyrgyzstan and Kazakhstan to determine priorities and agree on the interventions to be carried out in this seventh phase of the programme.
The meeting, which was held in Nur Sultan (Kazakhstan), was attended by representatives of the delegation of the European Union , which finances the project, officials from the Ministries of the Interior, Justice and Health, as well as members of the Prosecutor’s Office of Kazakhstan.
The meeting addressed the situation of drug use in the country and its recent developments, presented the objectives and results of the programme for the coming years, and identified the challenges facing this new phase.
This session, together with the one held previously in Bishkek (Kyrgyzstan), is part of the round of consultations that the CADAP programme team, together with the representatives of the European Union delegation, are carrying out in the five countries of the region during the start of the programme to adjust its content to the changes that the COVID19 pandemic has caused in drug distribution and consumption patterns.
The contributions of the participants and the debates generated during these meetings are very useful because they allow us to adapt the CADAP methodology of action to the priorities identified. All this in order to ensure the correct implementation and monitoring of the programme, both at the national and regional levels.
In the words of Mr Johannes Stenbaek-Madsen, head of cooperation of the EU delegation in the Republic of Kazakhstan, “the strategic vision of the EU in Central Asia is articulated through regional cooperation. Within the framework of this cooperation, CADAP 7 contributes to the reduction of the demand for drugs, prevention, and to the health care of drug users”.
The CADAP programme is an initiative of the European Union that began in 2003 and is currently in its seventh phase (2021-2024). This new phase is led by the FIIAPP with the strategic support of drug agencies from other EU member states and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).